BioNTech SE (BNTX)
NASDAQ
Closed
Aug 21, 2026
Day's Range
110.8952 wk Range
79.52Overview - BNTX - BioNTech SE
Key Statistics
Valuation
Enterprise Value
17.21B
P/E (Trailing)
‪160.80‬
P/E (Forward)
‪-20.51‬
PEG Ratio
‪1.56‬
Price / Sales (TTM)
‪11.05‬
Price / Book
‪1.41‬
EV / EBITDA
‪-10.65‬
Profitability
Gross Margin
‪8.14%‬
Profit Margin
‪-63.63%‬
Operating Margin
‪-806.62%‬
Return on Assets
‪-5.41%‬
Return on Equity
‪-9.30%‬
Ownership
Shares Outstanding
251.20M
Float
108.41M
Short % of Shares Outstanding
‪3.69%‬
Held by Insiders
‪57.51%‬
Held by Institutions
‪20.37%‬
Price stats
Beta
‪1.27‬
50-Day Avg
‪92.65‬
200-Day Avg
‪97.52‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
20 analysts
Average price target
‪$ 120.66‬Shariah Compliance
Report Date: Feb 19, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - BNTX - BioNTech SE
Peers - BNTX - BioNTech SE
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- BNTXNASDAQBioNTech SE29.28BMarket Cap+9.87%52-week change160.80P/E (Trailing)‪-63.63%‬Profit Margin
- ARGXNASDAQargenx SE American Depositary Receipt65.04BMarket Cap+34.86%52-week change39.69P/E (Trailing)‪32.26%‬Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals Inc31.60BMarket Cap-87.81%52-week change41.15P/E (Trailing)‪16.12%‬Profit Margin
- ASNDNASDAQAscendis Pharma A/S16.61BMarket Cap+24.84%52-week change19.38P/E (Trailing)‪70.84%‬Profit Margin
- BBIONASDAQBridgeBio Pharma, Inc.15.93BMarket Cap+41.98%52-week change-21.56P/E (Trailing)‪-97.02%‬Profit Margin
- BMRNNASDAQBiomarin Pharmaceutical Inc.12.91BMarket Cap+12.29%52-week change180.16P/E (Trailing)‪2.14%‬Profit Margin
- ARWRNASDAQArrowhead Pharmaceuticals Inc.12.30BMarket Cap+76.22%52-week change47.10P/E (Trailing)‪-47.79%‬Profit Margin
Profile Summary - BNTX - BioNTech SE
About
BioNTech SE is a German multinational biotechnology company headquartered in Mainz, specializing in the development of immunotherapies and vaccines for cancer and infectious diseases. Founded in 2008 by Uğur Şahin, Özlem Türeci, and Christoph Huber, it leverages advanced platforms like mRNA technology, next-generation…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
